2
|
Muniesa C, Gallardo F, García-Doval I, Estrach MT, Combalia A, Morillo-Andújar M, De la Cruz-Vicente F, Machan S, Moya-Martínez C, Rovira R, Sanchez-Gonzalez B, Acebo E, Amutio E, Peñate Y, Losada-Castillo MDC, García-Muret MP, Iznardo H, Román-Curto C, Cañueto J, Fernández-de-Misa R, Flórez Á, Izu RM, Torres-Navarro I, Zayas A, Pérez-Paredes G, Blanes M, Yanguas JI, Pérez-Ferriols A, Callejas-Charavia M, Ortiz-Romero PL, Pérez-Gil A, Prieto-Torres L, González-Barca E, Servitje O. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. J Eur Acad Dermatol Venereol 2023; 37:57-64. [PMID: 36017748 DOI: 10.1111/jdv.18563] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 08/05/2022] [Indexed: 12/15/2022]
Abstract
BACKGROUND Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. OBJECTIVES To evaluate the response and tolerance of BV in a cohort of patients with CTCL. METHODS We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). RESULTS Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. CONCLUSIONS These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.
Collapse
Affiliation(s)
- Cristina Muniesa
- Department of Dermatology, Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Dermatology, Hospital de Viladecans, Viladecans, Barcelona, Spain
| | - Fernando Gallardo
- Department of Dermatology, Hospital del Mar, IMAS-IMIM, Barcelona, Spain
| | | | - M Teresa Estrach
- Department of Dermatology, Hospital Clínic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
| | - Andrea Combalia
- Department of Dermatology, Hospital Clínic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
| | | | - Fátima De la Cruz-Vicente
- Department of Hematology, Hospital Universitario Vírgen del Rocío. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - Salma Machan
- Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain
| | | | - Roger Rovira
- Department of Dermatology, Hospital del Mar, IMAS-IMIM, Barcelona, Spain
| | | | - Elvira Acebo
- Department of Dermatology, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
| | - Elena Amutio
- Department of Hematology, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
| | - Yeray Peñate
- Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran, Canaria, Las Palmas, Spain
| | - Maria Del Carmen Losada-Castillo
- Department of Hematology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran, Canaria, Las Palmas, Spain
| | | | - Helena Iznardo
- Department of Dermatology, Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | | | - Javier Cañueto
- Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Ricardo Fernández-de-Misa
- Department of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - Ángeles Flórez
- Department of Dermatology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - Rosa María Izu
- Department of Dermatology, Hospital de Basurto, Bilbao, Spain
| | | | - Ana Zayas
- Department of Dermatology, Hospital Universitario Dr Peset, Valencia, Spain
| | - Gema Pérez-Paredes
- Department of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Mar Blanes
- Department of Dermatology, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain
| | - J Ignacio Yanguas
- Department of Dermatology, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
| | - Amparo Pérez-Ferriols
- Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain
| | | | - Pablo Luis Ortiz-Romero
- Department of Dermatology, Hospital Universitario 12 de Octubre, Institute I+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - Amalia Pérez-Gil
- Department of Dermatology, Hospital Universitario Vírgen de Valme, Sevilla, Spain
| | - Lucia Prieto-Torres
- Department of Dermatology, Hospital Universitario Lozano Blesa, Zaragoza, Spain
| | - Eva González-Barca
- Department of Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, L'Hospitalet de LLobregat, Barcelona, Spain
| | - Octavio Servitje
- Department of Dermatology, Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|